LEADERSHIP CORE- Leadership for the SPORE is based on an innovative interdisciplinary model. To address the needs of the projects, experts in ovarian cancer, translational research and genomics have been identified and recruited to serve as mentors for SPORE investigators who are expert in their own fields but less acquainted with other disciplines that are critical to progress in ovarian cancer translational research. Senior leaders with relevant expertise will interact with each other on a variety of substantitive committees to guide the scientific progress of the SPORE. The goal of the leadership core is to act as the foundation for scientific interaction, direction, mentoring, and program development. The senior investigators who comprise the Leadership Core share responsibility for the overall success of the SPORE, including development and use of a substantial ovarian cancer patient population, a specimen repository, and development of tools to reduce ovarian cancer incidence and mortality. The research proposed in the SPORE is translational. Its success is therefore measured by the degree to which it produces useful interventions that have an impact on outcomes. The nature of the research requires that decisions be made along the way about how the research should proceed. For example, which genes and gene products should be selected for development as markers of ovarian cancer or chemoresistance? Which gene products should be selected for possible development as vaccines? If vectors for the vaccines are not working, what can be done to solve the problem? A Translational Committee will address these questions in a collaborative spirit to facilitate the progress of the research projects. The Leadership Core also provides a consultation service. To assist the investigations in meeting their translational research objectives, experts in chemoresistance, translational research, behavior change, and early detection of ovarian cancer are available. Statisticians and mathematicians are also available to work with project investigators throughout the project period. They provide scientific review of protocols, power analyses, consulting regarding appropriate statistical analyses and cost- effectiveness analyses, and methods for identifying patterns of genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083636-03S1
Application #
6502467
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-30
Project End
2002-09-29
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874

Showing the most recent 10 out of 187 publications